Home/Filings/4/0001860010-23-000002
4//SEC Filing

ORTH ANDREW C. 4

Accession 0001860010-23-000002

CIK 0001711279other

Filed

Feb 27, 7:00 PM ET

Accepted

Feb 28, 6:45 PM ET

Size

9.0 KB

Accession

0001860010-23-000002

Insider Transaction Report

Form 4
Period: 2023-02-28
ORTH ANDREW C.
Chief Commercial Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2023-02-28+20,00020,000 total
    Exercise: $81.91Exp: 2033-02-28Common Stock (20,000 underlying)
  • Award

    Performance Stock Units

    2023-02-28+10,00010,000 total
    Common Stock (10,000 underlying)
Holdings
  • Common Stock

    100
Footnotes (5)
  • [F1]The option vests in four equal annual installments beginning on February 28, 2024.
  • [F2]Each performance stock unit ("PSU") represents a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement.
  • [F3]The number of PSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming achievement of all of the corporate performance criteria set by the Company's Compensation Committee for this award.
  • [F4]If any applicable portion of the performance criteria have been achieved, the award shall vest in two equal annual installments (February 28, 2024 and February 28, 2025).
  • [F5]If the performance criteria are not achieved, the portion of the award which was capable of vesting on that date will expire.

Issuer

Krystal Biotech, Inc.

CIK 0001711279

Entity typeother

Related Parties

1
  • filerCIK 0001860010

Filing Metadata

Form type
4
Filed
Feb 27, 7:00 PM ET
Accepted
Feb 28, 6:45 PM ET
Size
9.0 KB